[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"law-eurlex-dir_2009_120-de":3},{"abbreviation":4,"title":5,"source_type":6,"total":7,"offset":8,"entries":9},"dir_2009_120","zur Änderung der Richtlinie 2001\u002F83\u002FEG des Europäischen Parlaments und des Rates zur Schaffung eines Gemeinschaftskodexes für Humanarzneimittel im Hinblick auf Arzneimittel für neuartige Therapien","eurlex",43,0,[10,15,18,21,24,27,30,33,36,40,43,46,49,52,55,58,61,64,67,70,73,76,79,82,85,88,91,94,97,100,103,106,109,112,115,118,121,124,127,130,133,136,139],{"norm_key":11,"title":12,"chapter":13,"slug":14},"ErwGr. 1",null,"Erwägungsgründe","erwgr-1",{"norm_key":16,"title":12,"chapter":13,"slug":17},"ErwGr. 2","erwgr-2",{"norm_key":19,"title":12,"chapter":13,"slug":20},"ErwGr. 3","erwgr-3",{"norm_key":22,"title":12,"chapter":13,"slug":23},"ErwGr. 4","erwgr-4",{"norm_key":25,"title":12,"chapter":12,"slug":26},"Art. 1","art-1",{"norm_key":28,"title":12,"chapter":12,"slug":29},"Art. 2","art-2",{"norm_key":31,"title":12,"chapter":12,"slug":32},"Art. 3","art-3",{"norm_key":34,"title":12,"chapter":12,"slug":35},"Art. 4","art-4",{"norm_key":37,"title":38,"chapter":39,"slug":12},"Anhang.1","1. EINLEITUNG","Anhänge",{"norm_key":41,"title":42,"chapter":39,"slug":12},"Anhang.2","2. BEGRIFFSBESTIMMUNGEN",{"norm_key":44,"title":45,"chapter":39,"slug":12},"Anhang.3","2.1. Gentherapeutikum",{"norm_key":47,"title":48,"chapter":39,"slug":12},"Anhang.4","2.2. Somatisches Zelltherapeutikum",{"norm_key":50,"title":51,"chapter":39,"slug":12},"Anhang.5","3.1. Besondere Anforderungen an alle Arzneimittel für neuartige Therapien",{"norm_key":53,"title":54,"chapter":39,"slug":12},"Anhang.6","3.2.1.1. Gentherapeutikum, das eine oder mehrere rekombinante Nukleinsäuresequenzen, einen oder mehrere genetisch veränderte Mikroorganismen oder ein oder mehrere genetisch veränderte Viren enthält",{"norm_key":56,"title":57,"chapter":39,"slug":12},"Anhang.7","3.2.1.2. Gentherapeutikum, das genetisch veränderte Zellen enthält",{"norm_key":59,"title":60,"chapter":39,"slug":12},"Anhang.8","3.2.2. Besondere Anforderungen",{"norm_key":62,"title":63,"chapter":39,"slug":12},"Anhang.9","3.3.1. Einleitung: Fertigarzneimittel, Wirkstoff und Ausgangsstoffe",{"norm_key":65,"title":66,"chapter":39,"slug":12},"Anhang.10","3.3.2. Besondere Anforderungen",{"norm_key":68,"title":69,"chapter":39,"slug":12},"Anhang.11","3.3.2.1. Ausgangsstoffe",{"norm_key":71,"title":72,"chapter":39,"slug":12},"Anhang.12","3.3.2.2. Herstellungsverfahren",{"norm_key":74,"title":75,"chapter":39,"slug":12},"Anhang.13","3.3.2.3. Charakterisierungs- und Kontrollstrategie",{"norm_key":77,"title":78,"chapter":39,"slug":12},"Anhang.14","3.3.2.4. Hilfsstoffe",{"norm_key":80,"title":81,"chapter":39,"slug":12},"Anhang.15","3.3.2.5. Entwicklungsstudien",{"norm_key":83,"title":84,"chapter":39,"slug":12},"Anhang.16","3.3.2.6. Referenzmaterialien",{"norm_key":86,"title":87,"chapter":39,"slug":12},"Anhang.17","3.4.1. Medizinprodukte enthaltende Arzneimittel für neuartige Therapien gemäß Artikel 7 der Verordnung (EG) Nr. 1394\u002F2007",{"norm_key":89,"title":90,"chapter":39,"slug":12},"Anhang.18","3.4.2. Kombinierte Arzneimittel für neuartige Therapien gemäß der Definition in Artikel 2 Absatz 1 Buchstabe d der Verordnung (EG) Nr. 1394\u002F2007",{"norm_key":92,"title":93,"chapter":39,"slug":12},"Anhang.19","4.1. Besondere Anforderungen an alle Arzneimittel für neuartige Therapien",{"norm_key":95,"title":96,"chapter":39,"slug":12},"Anhang.20","4.2. Besondere Anforderungen an Gentherapeutika",{"norm_key":98,"title":99,"chapter":39,"slug":12},"Anhang.21","4.2.1. Pharmakologie",{"norm_key":101,"title":102,"chapter":39,"slug":12},"Anhang.22","4.2.2. Pharmakokinetik",{"norm_key":104,"title":105,"chapter":39,"slug":12},"Anhang.23","4.2.3. Toxikologie",{"norm_key":107,"title":108,"chapter":39,"slug":12},"Anhang.24","4.3.1. Pharmakologie",{"norm_key":110,"title":111,"chapter":39,"slug":12},"Anhang.25","4.3.2. Pharmakokinetik",{"norm_key":113,"title":114,"chapter":39,"slug":12},"Anhang.26","4.3.3. Toxikologie",{"norm_key":116,"title":117,"chapter":39,"slug":12},"Anhang.27","5.1. Besondere Anforderungen an alle Arzneimittel für neuartige Therapien",{"norm_key":119,"title":120,"chapter":39,"slug":12},"Anhang.28","5.2.1. Studien zur Pharmakokinetik am Menschen",{"norm_key":122,"title":123,"chapter":39,"slug":12},"Anhang.29","5.2.2. Studien zur Pharmakodynamik am Menschen",{"norm_key":125,"title":126,"chapter":39,"slug":12},"Anhang.30","5.2.3. Studien zur Unbedenklichkeit",{"norm_key":128,"title":129,"chapter":39,"slug":12},"Anhang.31","5.3.1. Somatische Zelltherapeutika, bei denen die Wirkungsweise auf der Produktion bestimmter aktiver Biomoleküle beruht",{"norm_key":131,"title":132,"chapter":39,"slug":12},"Anhang.32","5.3.2. Biodistribution, Persistenz und dauerhaftes Anwachsen von Bestandteilen somatischer Zelltherapeutika",{"norm_key":134,"title":135,"chapter":39,"slug":12},"Anhang.33","5.3.3. Studien zur Unbedenklichkeit",{"norm_key":137,"title":138,"chapter":39,"slug":12},"Anhang.34","5.4.1. Studien zur Pharmakokinetik",{"norm_key":140,"title":141,"chapter":39,"slug":12},"Anhang.35","5.4.2. Studien zur Pharmakodynamik"]